miR-340 reverses chemotherapy resistance in colon cancer via the PDCD4/WNT/β-catenin signalling pathway
8.0
来源：
Nature
关键字：
circRNA
发布时间：
2025-09-30 07:56
摘要：
miR-340 plays a crucial role in reversing chemotherapy resistance in colorectal cancer (CRC) by targeting the PDCD4/WNT/β-catenin signaling pathway. The study demonstrates that miR-340 is downregulated in oxaliplatin-resistant CRC cells, and its overexpression significantly enhances the sensitivity of these cells to oxaliplatin. This mechanism involves the suppression of drug resistance-related genes and proteins, highlighting miR-340's potential as a therapeutic target to improve chemotherapy efficacy in CRC.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分
business_impact
1.0分
scientific_rigor
1.5分
timeliness_innovation
1.5分
investment_perspective
2.5分
market_value_relevance
1.0分
team_institution_background
0.0分
technical_barrier_competition
0.5分
关键证据
miR-340 is downregulated in oxaliplatin-resistant CRC cells.
Overexpression of miR-340 enhances apoptosis and reduces cell viability.
miR-340 inhibits the WNT/β-catenin pathway, reversing drug resistance.
真实性检查
否
AI评分总结
miR-340 plays a crucial role in reversing chemotherapy resistance in colorectal cancer (CRC) by targeting the PDCD4/WNT/β-catenin signaling pathway. The study demonstrates that miR-340 is downregulated in oxaliplatin-resistant CRC cells, and its overexpression significantly enhances the sensitivity of these cells to oxaliplatin. This mechanism involves the suppression of drug resistance-related genes and proteins, highlighting miR-340's potential as a therapeutic target to improve chemotherapy efficacy in CRC.